Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,545 | -101,067 | -75,412 | -49,301 | -24,649 |
| Depreciation Amortization | 629 | 1,335 | 877 | 591 | 482 |
| Other Working Capital | -5,877 | 43,023 | 46,532 | 49,225 | 51,306 |
| Other Operating Activity | 6,437 | 24,843 | 18,510 | 12,048 | 5,352 |
| Operating Cash Flow | $-21,356 | $-31,866 | $-9,493 | $12,563 | $32,491 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -165 | -3,962 | -3,553 | -1,523 | -841 |
| Purchase Of Investment | N/A | -201,320 | -206,190 | -196,484 | -143,941 |
| Sale Of Investment | 53,250 | 159,400 | 141,371 | 62,371 | 9,000 |
| Investing Cash Flow | $53,085 | $-45,882 | $-68,372 | $-135,636 | $-135,782 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 44,901 | 45,838 | 46,366 | 45,932 | 42,507 |
| Other Financing Activity | 153 | 571 | 0 | 0 | 0 |
| Financing Cash Flow | $45,054 | $46,409 | $46,366 | $45,932 | $42,507 |
| Beginning Cash Position | 114,125 | 145,464 | 145,464 | 145,464 | 145,464 |
| End Cash Position | 190,908 | 114,125 | 113,965 | 68,323 | 84,680 |
| Net Cash Flow | $76,783 | $-31,339 | $-31,499 | $-77,141 | $-60,784 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,356 | -31,866 | -9,493 | 12,563 | 32,491 |
| Capital Expenditure | -165 | -3,962 | -3,553 | -1,523 | -841 |
| Free Cash Flow | -21,521 | -35,828 | -13,046 | 11,040 | 31,650 |